BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12192534)

  • 1. Immunotherapeutic potential of whole tumour cells.
    Ward S; Casey D; Labarthe MC; Whelan M; Dalgleish A; Pandha H; Todryk S
    Cancer Immunol Immunother; 2002 Sep; 51(7):351-7. PubMed ID: 12192534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.
    Ochsenbein AF; Sierro S; Odermatt B; Pericin M; Karrer U; Hermans J; Hemmi S; Hengartner H; Zinkernagel RM
    Nature; 2001 Jun; 411(6841):1058-64. PubMed ID: 11429607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination as immunotherapy for B cell lymphoma.
    Schultze JL
    Hematol Oncol; 1997 Aug; 15(3):129-39. PubMed ID: 9600112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM-CSF-based cancer vaccines.
    Dranoff G
    Immunol Rev; 2002 Oct; 188():147-54. PubMed ID: 12445288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy II: Antigens, receptors and costimulation.
    Searle PF; Young LS
    Cancer Metastasis Rev; 1996 Sep; 15(3):329-49. PubMed ID: 9034595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
    Braza MS; Klein B
    Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific immunotherapy of cancer in elderly patients.
    Matzku S; Zöller M
    Drugs Aging; 2001; 18(9):639-64. PubMed ID: 11599633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
    Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
    Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-specific vaccines for cancer treatment.
    Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antitumor immunity and cellular cancer therapies].
    Catros-Quemener V; Bouet F; Genetet N
    Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple pathways to tumor immunity and concomitant autoimmunity.
    Turk MJ; Wolchok JD; Guevara-Patino JA; Goldberg SM; Houghton AN
    Immunol Rev; 2002 Oct; 188():122-35. PubMed ID: 12445286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro.
    Dunnion DJ; Cywinski AL; Tucker VC; Murray AK; Rickinson AB; Coulie P; Browning MJ
    Immunology; 1999 Dec; 98(4):541-50. PubMed ID: 10594686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immune system and tumors].
    Terme M; Tanchot C
    Ann Pathol; 2017 Feb; 37(1):11-17. PubMed ID: 28159405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour immunology, vaccination and escape strategies.
    García-Lora A; Algarra I; Collado A; Garrido F
    Eur J Immunogenet; 2003 Jun; 30(3):177-83. PubMed ID: 12786993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.
    Rivoltini L; Carrabba M; Huber V; Castelli C; Novellino L; Dalerba P; Mortarini R; Arancia G; Anichini A; Fais S; Parmiani G
    Immunol Rev; 2002 Oct; 188():97-113. PubMed ID: 12445284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogene therapy.
    Lichtor T; Glick RP
    Adv Exp Med Biol; 2012; 746():151-65. PubMed ID: 22639166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.